Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ATR inhibition reverses the resistance of homologous recombination deficient MGMTlow/MMRproficient cancer cells to temozolomide

5 Oct 2021

Abstract excerpt

// Lara H. El Touny 1 , 8 , Curtis Hose 1 , John Connelly 1 , Erik Harris 1 , Anne Monks 1 , Angie B. Dull 2 , Deborah F. Wilsker 2 , Melinda G. Hollingshead 3 , Michelle Gottholm-Ahalt 3 , Sergio Y. Alcoser 3 , Michael E. Mullendore 4 , Ralph E. Parchment 2 , James H. Doroshow 5 , 6 , Beverly A. Teicher 6 , 7 and Annamaria Rapisarda 1 1 Molecular Pharmacology Laboratory, Leidos Biomedical Research Inc., FNLCR,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy
Share to Polyomavirus and related diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34676045
DOI: 10.18632/oncotarget.28090

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ATR inhibition reverses the resistance of homologous recombination deficient MGMTlow/MMRproficient cancer cells to temozolomidePMID 34676045Read ↗

MGMT function determines the differential response of ATR inhibitors with DNA-damaging agents in glioma stem cells for GBM therapySemantic proximity Read ↗

Functional Genomic Screens Reveal RBBP4 as a Key Regulator of Cell Cycle Progression in TMZ-Resistant GlioblastomaSemantic proximity Read ↗

Chemical screens identify HDAC6 as an epigenetic vulnerability in acquired Temozolomide-resistant models of glioblastomaSemantic proximity Read ↗

PARP Inhibitor Counteracts Temozolomide Resistance in Glioblastoma MultiformeSemantic proximity Read ↗

Temozolomide: Mechanisms of Action, Repair and ResistanceSemantic proximity Read ↗

Trans-Lesion Synthesis and Mismatch Repair Pathway Crosstalk Defines Chemoresistance and Hypermutation Mechanisms in GlioblastomaSemantic proximity Read ↗

Mechanism-based design of agents that selectively target drug-resistant gliomaSemantic proximity Read ↗

Mitigating Temozolomide Resistance in Glioblastoma via DNA Damage-Repair InhibitionSemantic proximity Read ↗

Loss of ATRX confers DNA repair defects and PARP inhibitor sensitivitySemantic proximity Read ↗

DNA Repair Capacity in Multiple Pathways Predicts Chemoresistance in Glioblastoma MultiformeSemantic proximity Read ↗

Novel Imidazotetrazine Evades Known Resistance Mechanisms and Is Effective against Temozolomide-Resistant Brain Cancer in Cell CultureSemantic proximity Read ↗

Mismatch repair proteins play a role in ATR activation upon temozolomide treatment in MGMT-methylated glioblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.